Quest study shows Haystack MRD test hits 100% specificity in DYNAMIC colorectal cancer cohort
DGX•A study found Quest Diagnostics’ Haystack MRD blood test had 100% specificity in a colorectal cancer specimen cohort and outperformed a commonly used blood biomarker for spotting recurrence.
1. Study findings
The Journal of Molecular Diagnostics study retrospectively tested stored samples from the DYNAMIC and DYNAMIC-III clinical trial programs. It found the test identified patients likely to relapse with no false alarms in the evaluated cohort, and outperformed a commonly used blood biomarker for spotting recurrence. The findings support broader clinical adoption and potential treatment-monitoring use.
